Biomarkers and precision oncology at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
92 organizations at ESMO 2026 present work in biomarkers & precision oncology: 53 cancer centres and hospitals, 25 universities and institutes, 6 industry and service companies, 6 drug developers and 2 societies and non-profits. Between them they bring 606 presentations to the program. Most represented: Gustave Roussy (40 on the program), Memorial Sloan Kettering Cancer Center (29 on the program), MD Anderson Cancer Center (21 on the program). 62 of them have their own page in this guide. As of Sep 29, 2026.
Format
Top represented
Showing 1–1 of 92 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
Gustave Roussy Villejuif, France | |
Comprehensive cancer centre in Villejuif, near Paris, France, affiliated with Paris-Saclay University. | Keynote Fri Oct 23 11:30–11:38 Talk Fri Oct 23 14:30–14:50 Therapeutic approaches in advanced/recurrent EC beyond CPIs and ADCs Gynaecological cancers Talk Fri Oct 23 16:15–16:35 Novel AR targeted therapies Genitourinary cancers Abstract Fri Oct 23 16:25–16:37 Invited Discussant 1243RO and 1244RO Gynaecological cancers Talk Fri Oct 23 16:30–16:45 Basket trials: When is enough, enough? Biomarkers & precision oncology Talk Sat Oct 24 08:30–08:50 Talk Sat Oct 24 08:30–08:50 Presentation by Expert Genitourinary cancers Chair Sat Oct 24 08:30–10:00 Abstract Sat Oct 24 08:35–08:40 Talk Sat Oct 24 08:40–08:50 Welcome from ESMO Nursing & supportive care Talk Sat Oct 24 09:10–09:30 Systemic approach Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 09:15–09:25 Abstract Sat Oct 24 09:45–09:55 Invited Discussant 1457O, 1458O and 1459O Haematological malignancies Abstract Sat Oct 24 10:15–10:20 Talk Sat Oct 24 11:30–11:37 Chair Sat Oct 24 12:00–12:50 ESMO-EACR: What oncologists should know about molecular oncology Biomarkers & precision oncology Chair Sat Oct 24 12:00–12:50 What oncologists should know about managing toxicities of novel therapies Nursing & supportive care Talk Sat Oct 24 12:15–12:30 Bispecifics Nursing & supportive care Talk Sat Oct 24 12:15–12:30 DNA repair Biomarkers & precision oncology Satellite Sat Oct 24 14:05–14:17 Nuclear Medicine: partner for the Prostate Cancer journey Genitourinary cancers Chair Sat Oct 24 14:45–16:15 Emerging toxicities induced by antibody-drug conjugates Nursing & supportive care Talk Sat Oct 24 14:45–15:10 Pulmonary toxicities Nursing & supportive care Talk Sat Oct 24 15:00–15:15 Pheochromocytoma and paraganglioma Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 15:15–15:35 How will new technologies contribute to precision medicine? Biomarkers & precision oncology Talk Sat Oct 24 15:20–15:35 View of the interventional radiologist Gastrointestinal cancers Talk Sat Oct 24 15:45–16:05 NUT carcinomas, salivary gland cancers and pulmonary blastomas Lung & thoracic cancers Talk Sat Oct 24 15:45–16:05 What to do after optimal neoadjuvant therapy? Breast cancer Chair Sat Oct 24 16:30–18:15 Presidential Symposium I Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Satellite Sat Oct 24 18:30–20:00 Ipsen - Treatment decisions that shape the journey in RCC and NETs Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:30–18:33 Welcome Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:33–18:43 Sequencing in an ever-changing landscape (RCC and NETs) Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:43–19:23 Navigating the RCC treatment journey Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 08:30–08:35 Chair Sun Oct 25 08:30–10:00 Rapid oral 2: NSCLC, metastatic Lung & thoracic cancers Chair Sun Oct 25 08:30–10:00 Chair Sun Oct 25 08:30–09:45 Abstract Sun Oct 25 08:35–08:40 4245RO - Complementary roles of Liquid Biopsy and Imaging in Assessing Tumor Burden in Metastatic Cancer Biomarkers & precision oncology Abstract Sun Oct 25 08:45–08:57 Talk Sun Oct 25 08:55–09:15 Abstract Sun Oct 25 08:57–09:02 Abstract Sun Oct 25 09:29–09:44 Invited Discussant 2618RO, 2652RO and 2680RO Lung & thoracic cancers Chair Sun Oct 25 10:15–11:45 Chair Sun Oct 25 10:15–11:45 Chair Sun Oct 25 10:15–11:45 Emerging new systemic therapies for RCC Genitourinary cancers Talk Sun Oct 25 10:15–10:35 Novel HIF2a targeted agents and combination strategies Genitourinary cancers Talk Sun Oct 25 10:45–11:00 Satellite Sun Oct 25 13:05–13:15 Building Bridges in the Management of CSCC Melanoma & skin cancers Satellite Sun Oct 25 13:10–13:40 Satellite Sun Oct 25 13:15–13:35 Resectable or Not: Navigating the Gray Zones in Advanced CSCC Melanoma & skin cancers Satellite Sun Oct 25 13:35–13:50 Defining High-risk CSCC: Identifying Patients Who Need More Melanoma & skin cancers Satellite Sun Oct 25 13:40–13:45 Audience Q&A: Advanced prostate cancer Genitourinary cancers Talk Sun Oct 25 13:45–14:00 Satellite Sun Oct 25 13:50–14:20 Timing and Selection of Systemic Therapy in Resectable CSCC Melanoma & skin cancers Satellite Sun Oct 25 14:20–14:30 Audience Q&A Melanoma & skin cancers Chair Sun Oct 25 14:45–16:25 Talk Sun Oct 25 15:10–15:30 Neoadjuvant therapy: A global prescription for cure Melanoma & skin cancers Abstract Sun Oct 25 15:44–15:49 1538RO - First Interim Safety analysis of GORTEC 2024-03 IDEAL: randomized phase II trial of induction treatment anti–PD-1 pucotenlimab (HX008) plus EGFR-ADC (becotatug vedotin (MRG003) versus EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 15:44–15:49 Abstract Sun Oct 25 16:05–16:15 Talk Sun Oct 25 16:30–16:55 Abstract Sun Oct 25 16:42–16:54 Invited Discussant LBA5 Lung & thoracic cancersGastrointestinal cancers Talk Mon Oct 26 08:30–08:50 Chair Mon Oct 26 08:30–10:00 Chair Mon Oct 26 08:30–10:00 Navigating the wave of new therapies in gynaecologic cancers Gynaecological cancers Abstract Mon Oct 26 08:40–08:50 Talk Mon Oct 26 09:10–09:30 Abstract Mon Oct 26 09:38–09:50 Invited Discussant 3084O, 3893O and 3894O Nursing & supportive care Chair Mon Oct 26 10:15–11:45 Addressing the risk of second primary cancers Nursing & supportive care Chair Mon Oct 26 13:00–14:30 Talk Mon Oct 26 13:25–13:35 Chair Mon Oct 26 14:45–15:45 Chair Mon Oct 26 14:45–16:15 Proffered paper: Non-metastatic NSCLC and other thoracic malignancies Lung & thoracic cancers Abstract Mon Oct 26 14:55–15:00 Talk Mon Oct 26 15:10–15:25 How to simplify the algorithm of treatment of rare endocrine tumors Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 15:12–15:17 Abstract Mon Oct 26 15:53–16:05 Invited Discussant LBA64, 2519O and 2511O Lung & thoracic cancers Chair Mon Oct 26 16:30–17:45 Chair Mon Oct 26 16:30–18:00 IO-based systemic therapy in head and neck cancers Sarcoma, CNS, head & neck and rare cancers Talk Mon Oct 26 16:30–16:35 Presentation of case/condition Nursing & supportive care Abstract Mon Oct 26 16:42–16:54 Invited Discussant LBA9 Gynaecological cancersSarcoma, CNS, head & neck and rare cancers Chair Tue Oct 27 09:00–13:00 Talk Tue Oct 27 12:40–13:00 |
Instantly find 20 buyers in biomarkers & precision oncology
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction